Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation

International Immunopharmacology

Volumn 44, Issue , 2017, Pages 174-182

  Afrin, Rejina ^a   Arumugam, Somasundaram ^a   Rahman, Azizur ^b   Wahed, Mir Imam Ibne ^a,c   Karuppagounder, Vengadeshprabhu ^a   Harima, Meilei ^a   Suzuki, Hiroshi ^a   Miyashita, Shizuka ^a   Suzuki, Kenji ^d   Yoneyama, Hiroyuki ^e   Ueno, Kazuyuki ^a   Watanabe, Kenichi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c UNIVERSITY OF RAJSHAHI   (Bangladesh)

^d NIIGATA UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e Stelic Institute of Regenerative Medicine   (Japan)

Author keywords

Curcumin; Fibrosis; HMGB1; NF B; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CCAAT ENHANCER BINDING PROTEIN BETA; CD68 ANTIGEN; CHOLESTEROL; CURCUMIN; CYTOCHROME P450 2E1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; GLYPICAN 3; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIVER PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTHROMBIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STREPTOZOCIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; VASCULOTROPIN; HMGB1 PROTEIN, MOUSE;

ADIPOGENESIS; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; ENERGY CONSUMPTION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIPID DIET; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER TISSUE; LIVER WEIGHT; MALE; MOUSE; NEWBORN; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEATOSIS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HUMAN; LIVER; LIVER NEOPLASMS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEOCYTOPLASMIC TRANSPORT; PATHOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANIMALS, NEWBORN; CARCINOMA, HEPATOCELLULAR; CURCUMIN; DISEASE MODELS, ANIMAL; FIBROSIS; HMGB1 PROTEIN; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; STREPTOZOCIN;

EID: 85009840523     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2017.01.016     Document Type: Article

References (47)

1. [1] Shariff, M.I., Cox, I.J., Gomaa, A.I., Khan, S.A., Gedroyc, W., Taylor-Robinson, S.D., Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol. 3 (2009), 353–367, 10.1586/egh.09.35.
2. [2] Mouralidarane, A., Soeda, J., Visconti-Pugmire, C., Samuelsson, A.-M., Pombo, J., Maragkoudaki, X., et al. Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice. Hepatology 58 (2013), 128–138, 10.1002/hep.26248.
3. [3] Ertle, J., Dechêne, A., Sowa, J.-P., Penndorf, V., Herzer, K., Kaiser, G., et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 128 (2011), 2436–2443, 10.1002/ijc.25797.
4. [4] Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol. 46 (2013), 141–152, 10.1007/s00795-013-0016-1.
5. [5] Farrell, G.C., van Rooyen, D., Gan, L., Chitturi, S., NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6 (2012), 149–171, 10.5009/gnl.2012.6.2.149.
6. [6] Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, Inflammation, and Cancer. 2010, 10.1016/j.cell.2010.01.025.
7. [7] Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R., Coyle, A.J., HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28 (2010), 367–388, 10.1146/annurev.immunol.021908.132603.
8. [8] DeMarco, R.A., Fink, M.P., Lotze, M.T., Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol. Immunol. 42 (2005), 433–444, 10.1016/j.molimm.2004.07.023.
9. [9] Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002), 191–195, 10.1038/nature00858.
10. [10] Tsung, A., Klune, J.R., Zhang, X., Jeyabalan, G., Cao, Z., Peng, X., et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 204 (2007), 2913–2923, 10.1084/jem.20070247.
11. [11] Tsung, A., Sahai, R., Tanaka, H., Nakao, A., Fink, M.P., Lotze, M.T., et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 0 (2005), 1135–1143, 10.1084/jem.20042614.
12. [12] Watanabe, K., Karuppagounder, V., Arumugam, S., Thandavarayan, R.A., Pitchaimani, V., Sreedhar, R., et al. Pruni cortex ameliorates skin inflammation possibly through HMGB1-NFκB pathway in house dust mite induced atopic dermatitis NC/Nga transgenic mice. J. Clin. Biochem. Nutr. 56 (2015), 186–194, 10.3164/jcbn.14-75.
13. [13] Karuppagounder, V., Arumugam, S., Thandavarayan, R.A., Pitchaimani, V., Sreedhar, R., Afrin, R., et al. Modulation of HMGB1 translocation and RAGE/NFκB cascade by quercetin treatment mitigates atopic dermatitis in NC/Nga transgenic mice. Exp. Dermatol. 24 (2015), 418–423, 10.1111/exd.12685.
14. [14] Dela Peña, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G., NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129 (2005), 1663–1674, 10.1053/j.gastro.2005.09.004.
15. [15] Chen, M., Liu, Y., Varley, P., Chang, Y., He, X.-X., Huang, H., et al. High-mobility group box 1 promotes hepatocellular carcinoma progression through miR-21-mediated matrix metalloproteinase activity. Cancer Res. 75 (2015), 1645–1656, 10.1158/0008-5472.CAN-14-2147.
16. [16] Soliman, M.M., Abdo Nassan, M., Ismail, T.A., Immunohistochemical and molecular study on the protective effect of curcumin against hepatic toxicity induced by paracetamol in Wistar rats. BMC Complement. Altern. Med., 14, 2014, 457, 10.1186/1472-6882-14-457.
17. [17] Fu, Y., Zheng, S., Lin, J., Ryerse, J., Chen, A., Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 73 (2008), 399–409, 10.1124/mol.107.039818.
18. [18] Afrin, R., Arumugam, S., Soetikno, V., Thandavarayan, R.A., Pitchaimani, V., Karuppagounder, V., et al. Curcumin ameliorates streptozotocin-induced liver damage through modulation of endoplasmic reticulum stress-mediated apoptosis in diabetic rats. Free Radic. Res. 49 (2015), 279–289, 10.3109/10715762.2014.999674.
19. [19] Marquardt, J.U., Gomez-Quiroz, L., Arreguin Camacho, L.O., Pinna, F., Lee, Y.-H., Kitade, M., et al. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J. Hepatol. 63 (2015), 661–669, 10.1016/j.jhep.2015.04.018.
20. [20] Gu, Q., Guan, H., Shi, Q., Zhang, Y., Yang, H., Curcumin attenuated acute Propionibacterium acnes-induced liver injury through inhibition of HMGB1 expression in mice. Int. Immunopharmacol. 24 (2015), 159–165, 10.1016/j.intimp.2014.12.005.
21. [21] Tu, C., Yao, Q., Xu, B., Wang, J., Zhou, C., Zhang, S., Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. Food Chem. Toxicol. 50 (2012), 3343–3351, 10.1016/j.fct.2012.05.050.
22. [22] Wang, C., Nie, H., Li, K., Zhang, Y., Yang, F., Li, C., et al. Curcumin inhibits HMGB1 releasing and attenuates concanavalin A-induced hepatitis in mice. Eur. J. Pharmacol. 697 (2012), 152–157, 10.1016/j.ejphar.2012.09.050.
23. [23] Liang, W., Menke, A.L., Driessen, A., Koek, G.H., Lindeman, J.H., Stoop, R., et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One, 9, 2014, e115922, 10.1371/journal.pone.0115922.
24. [24] Lillie, R.D., Further Experiments with the Masson Trichrome Modification of Mallory's Connective Tissue Stain, Stain Technol. http://www.tandfonline.com/doi/abs/10.3109/10520294009110327, 2009.
25. [25] Soetikno, V., Sari, F.R., Lakshmanan, A.P., Arumugam, S., Harima, M., Suzuki, K., et al. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol. Nutr. Food Res. 57 (2013), 1649–1659, 10.1002/mnfr.201200540.
26. [26] Kinoshita, M., Uchida, T., Sato, A., Nakashima, M., Nakashima, H., Shono, S., et al. Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in mice. J. Hepatol. 53 (2010), 903–910, 10.1016/j.jhep.2010.04.037.
27. [27] Cominacini, L., Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappa B through an increased production of intracellular reactive oxygen species. J. Biol. Chem. 275 (2000), 12633–12638, 10.1074/jbc.275.17.12633.
28. [28] Larter, C.Z., Yeh, M.M., Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 23 (2008), 1635–1648, 10.1111/j.1440-1746.2008.05543.x.
29. [29] Davila, J.A., Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors?. Am. J. Gastroenterol. 105 (2010), 632–634, 10.1038/ajg.2009.715.
30. [30] Lao, C.D., Ruffin, M.T., Normolle, D., Heath, D.D., Murray, S.I., Bailey, J.M., et al. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med., 6, 2006, 10, 10.1186/1472-6882-6-10.
31. [31] Csak, T., Velayudham, A., Hritz, I., Petrasek, J., Levin, I., Lippai, D., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 300 (2011), G433–G441, 10.1152/ajpgi.00163.2009.
32. [32] Mollica, L., De Marchis, F., Spitaleri, A., Dallacosta, C., Pennacchini, D., Zamai, M., et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 14 (2007), 431–441, 10.1016/j.chembiol.2007.03.007.
33. [33] Ikeda, K., Arase, Y., Kobayashi, M., Saitoh, S., Someya, T., Hosaka, T., et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig. Dis. Sci. 51 (2006), 603–609, 10.1007/s10620-006-3177-0.
34. [34] Shiota, G., Harada, K., Ishida, M., Tomie, Y., Okubo, M., Katayama, S., et al. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis 20 (1999), 59–63 ( http://www.ncbi.nlm.nih.gov/pubmed/9934850).
35. [35] Rendon-Mitchell, B., Ochani, M., Li, J., Han, J., Wang, H., Yang, H., et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170 (2003), 3890–3897 ( http://www.ncbi.nlm.nih.gov/pubmed/12646658).
36. [36] Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M., Ombrellino, M., Che, J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999), 248–251 ( http://www.ncbi.nlm.nih.gov/pubmed/10398600).
37. [37] Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 656–665, 10.1038/nrgastro.2013.183.
38. [38] Racanelli, V., Rehermann, B., The liver as an immunological organ. Hepatology 43 (2006), S54–S62, 10.1002/hep.21060.
39. [39] Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem. Biophys. Res. Commun. 336 (2005), 215–222, 10.1016/j.bbrc.2005.08.070.
40. [40] Gazit, V., Huang, J., Weymann, A., Rudnick, D.A., Analysis of the role of hepatic PPARγ expression during mouse liver regeneration. Hepatology 56 (2012), 1489–1498, 10.1002/hep.25880.
41. [41] Tang, D., Kang, R., Zeh Iii, H.J., Lotze, M.T., High-mobility group box 1, oxidative stress, and disease. Antioxid. Redox Signal. 14 (2016), 1315–1335.
42. [42] Wang, Y., Shan, J., Yang, W., Zheng, H., Xue, S., High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins. Inflammation 36 (2013), 1592–1604, 10.1007/s10753-013-9704-1.
43. [43] Li, B., Wang, L., Lu, Q., Da, W., Liver injury attenuation by curcumin in a rat NASH model: an Nrf2 activation-mediated effect?. Ir. J. Med. Sci., 2014, 10.1007/s11845-014-1226-9.
44. [44] Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 49 (2010), 1603–1616, 10.1016/j.freeradbiomed.2010.09.006.
45. [45] Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A., Ferrara, N., Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995), 1789–1797, 10.1172/JCI117857.
46. [46] Capurro, M., Wanless, I.R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 (2003), 89–97 ( http://www.ncbi.nlm.nih.gov/pubmed/12851874).
47. [47] Fujikawa, T., Shiraha, H., Yamamoto, K., Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Med. Okayama 63 (2009), 299–304 ( http://www.ncbi.nlm.nih.gov/pubmed/20035286).